table network network 2
demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only
COVID-19 severe or critically
COVID 19 outpatients
amubarvimab/romlusevimab (BRII-196 and BRII-198-Brii Biosciences) ACTIV-2 ...

0 studies excluded by filtering options 1

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons